ICOStomizing immunotherapies with T(H)17.
New insights on the role of costimulatory molecules in T helper cell function have yielded exciting alternatives to the development of therapeutic strategies that target T cell costimulatory pathways. Inducible costimulatory molecule (ICOS) signaling is now shown by Paulos and colleagues to support expansion of human T helper 17 (T(H)17) cells that could exert antitumor activity. Here we discuss (i) how these findings aid in our understanding of mechanisms that govern T(H)17 cell functions and (ii) the potential application of these new insights to the development of immunotherapies.
Garaude
Johan
J
Immunology Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
Blander
J Magarian
JM
D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D002454:Cell Differentiation / Q000276:immunology; D004847:Epithelial Cells / Q000276:immunology; D006706:Homeostasis; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D060889:Inducible T-Cell Co-Stimulator Protein; D015398:Signal Transduction / Q000276:immunology*; D058504:Th17 Cells / Q000276:immunology*
D000945:Antigens, Differentiation, T-Lymphocyte; C556692:ICOS protein, human; D060889:Inducible T-Cell Co-Stimulator Protein